Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.40 |
---|---|
High | 24.80 |
Low | 23.40 |
Bid | 24.60 |
Offer | 25.20 |
Previous close | 23.20 |
Average volume | 0.00 |
---|---|
Shares outstanding | 69.98m |
Free float | 68.84m |
P/E (TTM) | -- |
Market cap | 1.75bn USD |
EPS (TTM) | -3.20 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 15:30 GMT.
More ▼
Press releases
- Xencor Reports Third Quarter 2024 Financial Results
- Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
- Xencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
- Xencor Announces Upcoming Change to Board of Directors
- Xencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Xencor Announces Pricing of $175 Million Public Offering of Common Stock
- Xencor Announces Proposed Public Offering of Common Stock
- Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
- Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
More ▼